Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Banco de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Mult Scler ; 23(3): 442-446, 2017 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-27270497

RESUMEN

BACKGROUND: Alterations of intestinal permeability (IP) may contribute to the pathophysiology of immune-mediated diseases. OBJECTIVE: We investigated the possible association between IP changes and multiple sclerosis (MS). METHODS: We studied 22 patients with relapsing-remitting multiple sclerosis (RRMS) and 18 age- and sex-matched healthy donors (HDs), including five twin pairs (one concordant, and four discordant for disease). Measurement of lactulose (L) and mannitol (M; two non-metabolized sugars) levels in urine samples, after an oral load, allowed to quantify gut dysfunction. RESULTS: The proportion of participants with increased IP was significantly higher in patients than in HDs (16/22 (73%) versus 5/18 (28%); p = 0.001). Accordingly, the L/M urinary ratio showed significantly higher values in patients than in controls ( p = 0.0284). Urinary mannitol concentration was significantly lower in patients than in controls ( p = 0.022), suggesting a deficit of absorption from intestinal lumen. Such changes did not appear related to patients' clinical-radiological features. CONCLUSION: The relatively high proportion of IP changes in RR-MS patients seems to confirm our work hypothesis and warrants more work to confirm the result on a larger sample, and to understand the implications for related immunological disturbances and intestinal microbiota alterations. Our finding may also have relevance for oral treatments, recently introduced in clinical practice.


Asunto(s)
Microbioma Gastrointestinal/fisiología , Lactulosa/uso terapéutico , Manitol/uso terapéutico , Esclerosis Múltiple Recurrente-Remitente/tratamiento farmacológico , Adulto , Femenino , Fármacos Gastrointestinales/uso terapéutico , Microbioma Gastrointestinal/efectos de los fármacos , Humanos , Persona de Mediana Edad , Permeabilidad/efectos de los fármacos , Proyectos Piloto
3.
Lancet Healthy Longev ; 1(1): e11, 2020 10.
Artículo en Inglés | MEDLINE | ID: mdl-34173612
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA